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ABSTRACT 
 
Background: The present study was done to understand the incidence and type of breast lesions along with  
histological grading of malignant lesions in correlation with IHC receptor , in Histopathology department of Baroda 
medical college, Gujarat, India between December 2017 to October 2018.Method:All patients of all age groups 
with breast lesions were included in the study. Resected specimen and biopsies of breast lesions were submitted to 
the Histopathology section, Baroda Medical College for histopathological examination. H & E sections were studied 
and most suitable tissue block was selected for IHC evaluation in malignant cases. Results: Out of 152 cases, 76 
were benign, 10 were of Inflammatory pathology,67 were malignant and 64 cases were submitted for IHC. Out of  
46MRM cases of breast carcinoma in this study, Grading was done only in 43cases, as 1 case was of Invasive 
lobular carcinoma and 2cases were of Metaplastic carcinoma.Grade I tumors show 75% positivity in IHC groups 
{ER/PR+,Her2-}, while 35.48 % of  Grade II tumors show  {ER/PR+,Her2-}and  50% Grade III tumors shows{ 
ER/PR-,Her2-Conclusion:The spectrum of breast lesions consists of benign breast lesion as well as malignant breast 
lesions. Fortunately, most of the breast lesions are diagnosed as benign breast lesions. Breast carcinoma shows 
heterogeneity in its clinical behavior. Prognosis and management of breast carcinoma are influenced by classic 
variables such as histological type and grade, stage, tumor size, lymph node status, hormone receptor status of 
Estrogen (ER), Progesterone (PR) and Human epidermal growth factor receptor 2(Her2/neu) 
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INTRODUCTION  
The burden of breast cancer is increasing in both 
developed and developing countries, and in many 
regions of the world, it is the most frequently occurring 
malignant disease in women; comprising 18% of all 
female cancers, and worldwide, breast cancer is the 
fifth most common cause of cancer mortality. [1] In 
2008, approximately 1.4 million women were 
diagnosed with breast cancer worldwide with a 
corresponding of 460,000 deaths. [2] In India, breast 
carcinoma forms the second most common malignancy 
after cervical carcinoma and is detected in 20/1,00,000 
women. [3,4] Incidence of breast carcinoma is low in 
India compared to western countries, but it is 
associated with poor prognosis and high mortality, may 
be due to late presentation at advanced stages. [5] 
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The spectrum of breast lesions consists of benign 
breast lesion as well as malignant breast lesions. 
Fortunately, most of the breast lesions are diagnosed as 
benign breast lesions. Breast carcinoma shows 
heterogeneity in its clinical behavior. Prognosis and 
management of breast carcinoma are influenced by 
classic variables such as histological type and grade, 
stage, tumor size, lymph node status, hormone receptor 
status of Estrogen (ER), Progesterone (PR) and Human 
epidermal growth factor receptor 2 (Her2/neu). Though 
hormone receptor analysis is a prerequisite in this era, 
for management and prognosis, still histopathological 
grading can be taken up as an important variable for 
predicting prognosis. [6] Determining the estrogen 
receptor (ER), progesterone receptor (PR) and 
Her2/neu receptor status in breast carcinoma has 
become practice as survival advantage for patients with 
hormones receptor positive status by treatment with 
adjuvant hormonal or chemotherapeutic regimen. It is 
well known that strong ER-positive cases benefit from 
endocrine therapy alone, in contrast to those with low 
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to moderate ER positivity. [7] PR status is 
independently associated with disease-free and overall 
survival. Patients with ER, PR positive tumors have a 
better prognosis than patients with negative expression 
of ER and PR tumors. [8] 
 
MATERIALS AND METHODS 
 
The present study was conducted at the Department of 
Pathology, Medical College Baroda and SSG hospital. 
The test population comprised of patients in all age 
group, with breast pathology, between December 2017 
to October 2018.Resected specimen and biopsies of 
breast lesions were submitted to the Histopathology 
section, Baroda Medical College for histopathological 
examination. Data for prospective study were obtained 
from tissue specimens received in the histopathology 
section in the specified period of study. The tissues of 
the test population submitted were evaluated by 
histopathological processing and examination (HPE), 
the most suitable tissue block was selected for IHC 
evaluation. During the HPE reporting, most of the 
cases were diagnosed by light microscopy and 
subsequently, ER, PR and Her2 were done on the best 
section representing the tumor. Cases were diagnosed 
as benign, malignant along with IHC performed on 
Malignant cases. 
 
RESULTS
All 152 cases were evaluated histopathologically. 10 cases were of  Inflammatory pathology [Table 1], 76 cases 
were benign [Table 2] and 67 cases were malignant [Table 3]. 
Table 1: Incidence of Inflammatory lesions 
Type of lesion No. Of cases Percentage 
Breast abscess 03 30% 
Chronic mastitis 02 20% 
Granulomatous mastitis 03 30% 
Duct ectasia 02 20% 
Total 10  
The most common inflammatory lesion was  granulomatous mastitis [Figure 1] and breast abscess followed by 
chronic mastitis and duct ectasia [Figure 2]. 
 
Figure 1: Granulomatous mastitis, H&E stain                                 Figure 2:Duct ectasia, H & E stain, 10 X” 
            10 X 
Table 2: Incidence of benign lesions 
Type of lesion No. of cases Percentage 
Fibroadenoma 49 64.47% 
Fibrocystic disease 02 2.63% 
Nodular  adenosis 01 1.31% 
Tubular adenoma 01 1.31% 
Ductal adenoma 01 1.31% 
Benign phyllodes tumor 11 14.47% 
Intraductal papilloma 01 1.31% 
 usual ductal hyperplasia 03 3.95% 
Atypical lobular hyperplasia 01 1.31% 
Gynecomastia 06 7.9% 
Total 76 100 % 
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The most common benign breast disease was fibroadenoma forming the major bulk with 49 cases out of the total 76 
cases of benign breast diseases. It was followed by 11 cases of Benign Phyllodes tumor (11 cases) and 6 cases of 
gynecomastia . There were 3 cases of Usual ductal hyperplasia, 2 cases of Fibrocystic disease and 1 case each of 
nodular adenosis [Figure 3], tubular adenoma, ductal adenoma, atypical lobular hyperplasia and intraductal 
papilloma [Figure 4]. 
 
 
Figure 3: Nodular adenosis, H&E stain, 10 X         Figure 4: Ductal Papilloma, H&E stain, 10 X 
 
 
Table 3: Incidence of malignant lesions 
Type of lesion No. of cases Percentage 
Ductal carcinoma in situ 01 1.49% 
Invasive ductal carcinoma-nos 60 89.55% 
Invasive lobular carcinoma 01 1.49% 
Metaplastic carcinoma 02 2.98% 
Malignant phyllodes 02 2.98% 
Lymphoma 01 1.49% 
Total 67 100 % 
Out of the 67 cases of malignant lesion in our study, most common  was IDC-NOS(60 cases)[Figure 5]. There were 
2 cases of Metaplastic carcinoma and 1 case of Ductal carcinoma in situ [Figure 6].There were 2 cases of malignant 
phyllodes tumor  and 1 case of diffuse large B-cell lymphoma. 
 
Figure 5: Invasive ductal carcinoma, H&E, 40 X       Figure 6:Ductal carcinoma in situ, H&E, 40 X 
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IHC was carried out in 64 cases out of 67 diagnosed 
malignant cases as 1 case was of lymphoma and 2 
cases were metaplastic carcinoma of breast. There were  
46 MRM specimen of breast carcinoma, 43 cases were 
of  IDC NOS type ,out of which 4 were of histological 
Grade I (9.30%) with 75 % positivity for ER/PR+ 
&Her2 -.31 were of histological Grade II (72.09%) 
with 35.48 % positivity for ER/PR & Her2 -. 8 cases 
were of histological Grade III (18.6% with 50 % 
showing negative results for ER/PR & Her2 . 2 cases 
were of Metaplastic carcinoma where histological 
grading was not done but showed triple negativity in 1 
cases for ER/PR and Her2/neu. 1 case was of Invasive 
lobular carcinoma where also histological grading was 
not done but was positive for ER/PR and negative for 
Her2/neu. Maximum numbers of Grade I tumors were 
seen in patients of 51-60 years of age group implying a 
better prognosis, while Grade II and Grade III tumors 
were more common in 41-50 years of age, with 
maximum number of triple negative cases implying a 
worse prognosis[Table 4].  
Table 4:Distribution of cases according to Histological grade and IHC results 
 Grade I Grade II Grade III Total 
ER/PR+,Her2+ 01(25%) 06(19.35%) 00 07(16.28%) 
ER/PR+,Her2- 03(75%) 11(35.48%) 02(25%) 16(37.21) 
ER/PR-,Her2+ 00 05(16.13%) 02(25%) 07(16.28%) 
ER/PR-,Her2- 00 09(29.03%) 04(50%) 13(30.23%) 
Total 04(100%) 31(100%) 08(100%) 43(100%) 
 
DISCUSSION 
In the present study, out of the 152 cases studied, 8 
cases (5.26 %) were inflammatory lesions, the most 
common being granulomatous mastitis and breast 
abscess in age group31-40 years. The probable reason 
behind this is that most of the inflammatory lesions in 
our tertiary set up are diagnosed by FNAC and 
managed conservatively so biopsy is not required.76 
cases (50 %) were benign. Most of the benign cases 
were in the age group of 21-30 years closely followed 
by 11-20 years . In accordance with the past studies, in 
the present study also, the most common benign breast 
lesion was found to be fibroadenoma constituting a 
total of 49 cases (64.47% of the total benign breast 
diseases and 32.23% of the total breast lesions). 
Fibroadenoma occupied 66.86% of the total benign 
cases studied by Mansoor et al [9] 70.83% in study of 
Vissa Shanthi et al[10] 71.3% in study of Aslam et 
al[11]. This clearly concludes that Fibroadenoma is the 
most common benign breast lesion. In the present 
study, 67 cases were malignant (44.07%). The finding 
that breast cancer was higher in this study probably 
because being a tertiary health care facility, most of the 
patients admitted here are referred malignant cases 
from the periphery and the growing environment of 
private owned hospitals by general practitioners where 
most of the benign lesions are probably managed. In 
this study, most of the malignant cases were found to 
be in the age group of 41-50 years (n=20, 66.67%). The 
most common breast cancer was found to be 
infiltrating ductal carcinoma-not otherwise specified 
type (IDC-NOS) constituting a total of 60 cases 
(89.55%). This is similar to the past studies conducted 
by Mansoor et al [8]Vissa Shanthi et al [10], Aslam et 
al.[11] By seeing the above data we can conclude that 
IDC-NOS is the most common breast carcinoma. The 
age of patients ranged from 25 to 80years, with a mean 
age group of 39.13 years. Maximum number of cases 
were seen in the age group of 41-50 years (31.25%) 
followed by 61-70 years (21.87%). In our study, mean 
age is slightly lower compare to other studies probably 
due to awareness programs has increased screening and 
early diagnosis of breast carcinoma in community. 
Distribution pattern of breast cancer according to 
tumor grade and ER/PR, Her2/neustatus 
 In our study ER positivity was expressed 100% 
(4cases) in Grade I, 48.39% (15cases) in Grade II and 
37.5% (3cases) in Grade III tumors respectively.  
Similar results were observed by Azizun Nisa et al 
[12]showing  ER positivity in 70% cases in Grade I, 
48.2% cases in Grade II and 3.5% cases in Grade III 
tumors respectively.  In the study done by Bhagat et 
al[20] showing  ER positivity in 50% cases in Grade I, 
56% cases in Grade II and 35.2 % cases in Grade III 
tumors respectively. In the study done by Amit et al[13] 
ER positivity was expressed in 86.66% cases in grade 
I, 57.14% cases in grade II and 4% cases in grade III 
tumors while in study done by Rana  et al [14]  ER 
positivity was seen in 84.21% of grade I and 78.26% 
cases of grade II tumors. All cases of grade III tumor 
was ER negative. In the study done by Nandam et al [3] 
ER positivity was present in 100% cases in Grade I, 
31.25% cases in Grade II and 25 % cases in Grade III 
tumors respectively [Table 5] 
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Table 5 : Distribution of cases according to tumor grade and ER status 
Grade ER+ 
AzizunNisa et al 
ER+ 
Bhagat et al 
ER+ 
Amit et al 
ER+ 
Rana et al 
ER+ 
Nandam et al 
ER+ 
Present study 
I 70% 50% 86.66% 84.21% 100% 04(100%) 
II 48.2% 56% 57.14% 78.26% 31.25% 15(48.39%) 
III 3.5% 35.2% 4% 0% 25% 03(37.5%) 
 
While PR positivity was expressed 100% (4cases) in 
Grade I, 54.84% (17 cases) in Grade II and 12.5% (1 
case) in Grade III tumors respectively. Similar results 
were observed by Azizun Nisa et al[12]showing  PR 
positivity was expressed 70 %cases in Grade I, 36.1% 
cases in Grade II and 1.75%  cases in Grade III tumors 
respectively. In the study done by Bhagat et al[15] 
showing  PR positivity in 43.75 % cases in Grade I, 
40% cases in Grade II and 29.1 %  cases in Grade III 
tumors respectively. Similar results were also seen in 
studies done by Rana et al [14] and Nandam et al [3] 
[Table 6] 
Table 6 : Distribution of cases according to tumor grade and PR status 
 
Grade PR+ 
Azizun Nisa et al 
PR+ 
Bhagat et al 
PR+ 
Amit et al 
PR+ 
Rana et al 
PR+ 
Nandam et al 
PR+ 
Present study 
I 70% 43.75% 86.66% 89.47% 50% 04(100%) 
II 36.1% 40% 57.14% 60.87% 25% 17(54.84)% 
III 1.75% 29.1% 8% 7.14% 25% 01(12.5%) 
 
In our study Her2/neupositivity was expressed in 25%, 
35.48% and 25% in Grade I, II and III respectively 
which correlate well with study done by Geethamala et 
al [16]in which Her2/neu positivity was expressed 
15.8%,27.8% and 26.4 % in Grade I,II and III 
respectively. In studies by AzizunNisa et al[12]0%, 
22.9%, 31.6% in Grade I, II and III respectively and 
Bhagat et al[15] shows 0%, 28%, 52.94% in Grade I, II 
and III respectively were Her2/ neu positive.[Table 7] 
 
Table 7: Distribution of cases according to tumor grade and Her2/neu status 
Grade Her2Neu+ 
Azizun Nisa et 
al 
Her2Neu+ 
Bhagat et al 
Her2Neu+ 
Geethamala K et 
al 
Her2Neu+ 
VissaShanthi et al 
Her2Neu+ 
Present study 
I 0% 0% 15.8% 25% 01(25%) 
II 22.9% 28% 27.8% 57.14% 11(35.48%) 
III 31.6% 52.94% 26.4% 60% 02(25%) 
 
       Distribution pattern of breast cancer according to 
ER, PR andHer2/neustatus: Her2/neupositivity in 
present study was 34.38% which is similar to the 
studies done by Vaidhyanathan et al[17]with  43.2% and 
Munjal et al[18] with 40.2% positivity  in their study. 
While studies done  by Bhagat et al[15]showed 27.58% 
positivity, Ambroise et al[19] showed 27.10% positivity 
and  Sharif et al [6] showed 28% positivity respectively 
in their study.[Table 8,9] 
 
Table 8 : Distribution of cases according to ER, PR status 
 Bhagat et al Ambroise et al Amit et al Present study 
ER+PR+ 36.20% 47.0% 45.16 43.75% 
ER+PR- 12.06% 12.2% 4.84 9.38% 
ER-PR+ 1.72% 4.05% 6.45 9.38% 
ER-PR- 48.27% 36.8% 43.55 37.5% 
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Table 9 : Distribution of cases according to Her2/neu status 
 Bhagat et al Munjal et al Ambroise et 
al 
Sharif et 
al 
Vaidhyanathan et al Present 
study 
Her2/neu+ 27.58% 40.2% 27.10% 28% 43.2% 34.38% 
 
The triple negative breast carcinoma is characterized by lack of ER, PR and Her2/neuexpression. Present study 
showed 28.12% cases with Negative ER, PR and Her2/neustatus  
 
CONCLUSION  
 
From the present study we can conclude that most 
common breast lesions are benign, in age group 21-30 
years, fibroadenoma being the most common. This is 
followed by malignant lesions, Infiltrating Ductal 
Carcinoma-NOS type being the most common in age 
group 41-50 years. Inflammatory lesions are not so 
common constituting to only 5.26 % of all cases. Most 
common histological grade is Grade II for Infiltrating 
Ductal carcinoma (NOS) of Grade I tumors seen in 
patients of 51-60 years of age group imply a better 
prognosis than Grade II and Grade III tumors which 
were more common in 41-50 years of age. Based on 
the IHC profile of breast cancer in this study, ER/PR 
showed more positivity in Grade I than in Grade II & 
III tumors. Triple negative Grade III tumors are 
associated with poor prognosis. Thus Prognostic 
accuracy improves with incorporation of IHC into the 
histopathology report along with the traditional TNM 
staging and histological grading.  
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